Microbial contamination of syringes during preparation: The direct influence of environmental cleanliness and risk manipulations on end-product quality

American Journal of Health-System Pharmacy

Volumn 66, Issue 22, 2009, Pages 2032-2036

  Stucki, Cyril ^a   Sautter, Anna Maria ^a   Favet, Jocelyne ^b   Bonnabry, Pascal ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Aseptic areas; Compounding; Contamination; Injections; Laminar flow; Pharmacy, hospital; Standards; Syringes

Indexed keywords

AMBIENT AIR; ARTICLE; ENGINEERING; ENVIRONMENTAL SANITATION; FUNGAL CONTAMINATION; HEALTH CARE ORGANIZATION; HIGH RISK BEHAVIOR; LAMINAR AIRFLOW; MICROBIAL CONTAMINATION; OPERATING ROOM; PHARMACY; PRIORITY JOURNAL; SYRINGE;

EID: 70450168878     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070681     Document Type: Article

References (22)

1. Simmons BP, Hooton TM, Wong ES et al. Centers for Disease Control guidelines on infection control: guidelines for prevention of intravascular infections. Atlanta: Centers for Disease Control; 1981. PB84-923403.
2. Taxis K, Barber N. An ethnographic study of incidence and severity of intravenous drug errors. BMJ. 2003; 326:684-687 (Pubitemid 36390447)
3. Gonzalez S, Miller D, Murphy SP. Maintenance of sterility in 1-mL polypropylene syringes. Am J Health-Syst Pharm. 2007; 64:1962-1964 (Pubitemid 47462913)
4. Bennett SN, McNeil MM, Bland LA et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med. 1995; 333:147-54.
5. Crowther J, Hrazdil J, Jolly DT et al. Growth of microorganisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Anesth Analg. 1996; 82:475-478 (Pubitemid 26072947)
6. Kettaneh A, Weill FX, Poilane I et al. Septic shock caused by Ochrobactrum anthropi in an otherwise healthy host. J Clin Microbiol. 2003; 41:1339-1341 (Pubitemid 36307157)
7. Harbarth S, Sudre P, Dharan S et al. Outbreak of Enterobacter cloacae related to understaffing, overcrowding, and poor hygiene practices. Infect Control Hosp Epidemiol. 1999; 20:598-603.
8. Yu HP, Tang GJ, Liaw WJ et al. Pseudomonas cepacia induced septic shock after propofol - a case report. Acta Anaesthesiol Sin. 2000; 38:53-56
9. Wachowski I, Jolly D, Hrazdil J et al. The growth of microorganisms in propofol and mixtures of propofol and lidocaine. Anesth Analg. 1999; 88:209-212 (Pubitemid 29025175)
10. Thomas M, Sanborn MD, Couldry R. I.V. admixture contamination rates: traditional practice site versus a class 1000 cleanroom. Am J Health-Syst Pharm. 2005; 62:2386-2392 (Pubitemid 41705192)
11. Trissel LA, Gentempo JA, Anderson RW et al. Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk-level compounding. Am J Health-Syst Pharm. 2005; 62:285-288
12. Trissel LA, Ogundele AB, Ingram DS et al. Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compounding. Am J Health-Syst Pharm. 2003; 60:1853-1855
13. McConaghy P, McCallum J, McCaughey W. Contamination of opioids during preparation for regional anaesthesia. Anaesthesia. 1996; 51:1079-1080 Letter. (Pubitemid 26377200)
14. Pharmaceutical compounding - sterile preparations (general information chapter 797). In: The United States pharmacopeia, 27th rev., and The national formulary, 22th ed. Rockville, MD: United States Pharmacopeial Convention; 2004.
15. Hecq JD. Centralized intravenous additive service (CIVAS). Implementation manual for Belgian hospital pharmacists. Brussels: Beroepsvereniging van de Vlaamse ziekenhuisapothekers-Association beige des pharmaciens hospitaliers; 1999.
16. Cousins DH. Centralized intravenous additive service. Implementation manual. London: Pharmaceutical Press; 1990.
17. American Society of Health-System Pharmacists. ASHP guidelines on quality assurance for pharmacy-prepared sterile products. Am J Health-Syst Pharm. 2000; 57:1150-1169
18. Cadman B. Reducing the risk of IV drug administration in critically ill patients. Hosp Pharm. 1999; 6:213-218
19. Van Grafhorst JP, Foudrain NA, Nooteboom F et al. Unexpected high risk of contamination with staphylococci species attributable to standard preparation of syringes for continuous intravenous drug administration in a simulation model in intensive care units. Crit Care Med. 2002; 30:833-836 (Pubitemid 34297803)
20. Stucki C, Sautter AM, Bonnabry P. Contribution à l'amélioration de la sécurisation du processus du médicament en anesthésiologie. pharmacie.hug-ge.ch/ens/mas/ diplome-cs.pdf (accessed 2005 Dec).
21. Joubert KE, Picard J, Sethusa M. Inhibition of bacterial growth by different mixtures of propofol and thiopentone. J S Afr Vet Assoc. 2005; 76:85-89 (Pubitemid 44696489)
22. Vidovich MI, Peterson LR, Wong HY. The effect of lidocaine on bacterial growth in propofol. Anesth Analg. 1999; 88:936-938